Weight loss and breast cancer incidence in postmenopausal women
- PMID: 30294816
- PMCID: PMC6890496
- DOI: 10.1002/cncr.31687
Weight loss and breast cancer incidence in postmenopausal women
Abstract
Background: Although obesity is an established risk factor for postmenopausal breast cancer, the results of weight loss and breast cancer studies are inconsistent. Therefore, we evaluated associations between weight change and breast cancer risk in postmenopausal women in the Women's Health Initiative Observational Study.
Methods: Postmenopausal women (n = 61,335) who had no prior breast cancer and a normal mammogram had body weight and height measured and body mass index (BMI) calculated at baseline and year 3. Weight change at year 3 was categorized as stable (<5%), loss (≥5%), or gain (≥5%) with further assessment of weight loss intentionality by self-report. Multivariable Cox proportional hazard regression models were used to evaluate relationships between weight change and subsequent breast cancer incidence.
Results: During a mean follow-up of 11.4 years with 3061 incident breast cancers, women with weight loss (n = 8175) had a significantly lower risk of breast cancer compared with women whose weight remained stable (n = 41,139) (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.78-0.98; P = .02) with no interaction by BMI. Adjustment for mammography did not alter findings (HR, 0.88; 95% CI, 0.78-0.99) with no significant difference by weight loss intentionality. Weight gain (≥5%) (n = 12,021) was not associated with breast cancer risk (HR, 1.02; 95% CI, 0.93-1.11) but was associated with higher triple-negative breast cancer incidence (HR, 1.54; 95% CI, 1.16-2.05).
Conclusions: Postmenopausal women who lose weight have lower breast cancer risk than those with stable weight. These findings suggest that postmenopausal women who lose weight may reduce their breast cancer risk.
Keywords: Women’s Health Initiative; breast cancer; obesity; weight loss; weight loss intentionality.
© 2018 American Cancer Society.
Conflict of interest statement
Conflict of Interest Disclosures
Dr. Chlebowski reported being a consultant for AstraZeneca, Novartis and Pfizer. No other author reported conflicts.
Figures
References
-
- Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002; 20:1128–43. - PubMed
-
- Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010; 123:627–35. - PubMed
Publication types
MeSH terms
Grants and funding
- N01WH32119/WH/WHI NIH HHS/United States
- N01WH42107/HL/NHLBI NIH HHS/United States
- N01 WH022110/WH/WHI NIH HHS/United States
- N01WH42129/WH/WHI NIH HHS/United States
- R21 CA100720/CA/NCI NIH HHS/United States
- N01WH24152/WH/WHI NIH HHS/United States
- N01WH32122/WH/WHI NIH HHS/United States
- N01WH32115/WH/WHI NIH HHS/United States
- N01WH32118/HL/NHLBI NIH HHS/United States
- N01WH32108/WH/WHI NIH HHS/United States
- N01WH44221/WH/WHI NIH HHS/United States
- N01WH32111/WH/WHI NIH HHS/United States
- N01WH32100/WH/WHI NIH HHS/United States
- N01WH32105/HL/NHLBI NIH HHS/United States
